HealthcareFirms.com » Cardiovascular Drugs

Regenerx Biopharmaceuticals Inc.

admin — Tue, 02 Mar 2010 18:40:16 +0000

RegeneRx is focused on the discovery and development of novel peptides to accelerate tissue and organ repair. Currently, RegeneRx is developing three product candidates, RGN-137, RGN-259 and RGN-352 for dermal, ophthalmic, and cardiovascular tissue repair, respectively. These product candidates are based on TB4, a synthetic copy of a 43-amino acid, naturally occurring peptide, in part, under an exclusive world-wide license from the National Institutes of Health. RegeneRx holds over 60 world-wide patents and patent applications related to novel peptides. It is currently in Phase 2 clinical development for dermal and ophthalmic wound healing and has now completed a Phase 1 clinical trial supporting delivery of RGN-352 for acute cardiovascular and other indications requiring systemic administration. RegeneRx is also developing novel peptides for the cosmeceutical industry based on its experience with TB4 and its biological activities in the skin.

Geron Corporation

admin — Tue, 02 Mar 2010 18:40:16 +0000

Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure and diabetes. The company is advancing an anti-cancer drug and a cancer vaccine that target the enzyme telomerase through multiple clinical trials in different cancers.

Arena Pharmaceuticals, Inc.

admin — Fri, 26 Feb 2010 18:31:21 +0000

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors, an important class of validated drug targets, in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena’s most advanced drug candidate, lorcaserin, is intended for weight management, including weight loss and maintenance of weight loss, and has completed a pivotal Phase 3 clinical trial program. Arena recently submitted an NDA for lorcaserin to the FDA.

Osiris Therapeutics, Inc.

admin — Sun, 21 Feb 2010 18:37:26 +0000

Osiris Therapeutics, Inc. is the leading stem cell therapeutic company focused on developing products to treat serious medical conditions in the inflammatory, orthopedic and cardiovascular areas. The Company’s pipeline of internally developed biologic drug candidates under evaluation includes Prochymal for inflammatory, autoimmune and cardiovascular indications, as well as Chondrogen for arthritis in the knee. Osiris is a fully integrated company, with capabilities in research, development, manufacturing and distribution of stem cell products.

Oxigene Inc.

admin — Sun, 21 Feb 2010 18:37:26 +0000

OXiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases. The company’s major focus is developing vascular disrupting agents (VDAs) that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment.

PolyMedix, Inc.

admin — Sun, 21 Feb 2010 18:37:26 +0000

PolyMedix is focused on the development of novel drugs and biomaterials for the treatment of infectious diseases and acute cardiovascular disorders. PolyMedix’s compounds are based on biomimetics: non-peptide small molecule drugs that mimic the activity of proteins. The Company’s antibiotic compounds are small molecule mimetics of human host-defense proteins and believed to have a completely different mechanism of action from all current antibiotic drugs. A mechanism which is intended to make bacterial resistance unlikely to develop. These compounds are being developed as broad spectrum, rapid-acting antibiotics for serious systemic and local infections. The Company is also developing polymeric formulations as antimicrobial biomaterials, which can be used as additives to paints, plastics, and textiles to create self-sterilizing products and surfaces. The Company’s anticoagulant antagonist compounds reverse the activity of both heparin and low molecular weight heparins, in keeping with its goal of developing an antagonist drug that is safer and easier to use than current approved therapy.

Opexa Therapeutics, Inc.

admin — Sun, 21 Feb 2010 13:59:35 +0000

Opexa Therapeutics, Inc. is dedicated to the development of patient-specific cellular therapies for the treatment of autoimmune diseases. The Company’s leading therapy, Tovaxin®, is an individualized cellular immunotherapy treatment in Phase IIb clinical development for multiple sclerosis (MS). Tovaxin is derived from T-cells isolated from peripheral blood, expanded ex vivo, and reintroduced into the patients via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin and, thereby, reduces the risk of relapse over time.

Molecular Insight Pharmaceutical

admin — Sun, 21 Feb 2010 13:59:34 +0000

Molecular Insight Pharmaceuticals is a clinical-stage biopharmaceutical company and a pioneer in the emerging field of molecular medicine. The Company is focused on the discovery and development of therapeutic radiopharmaceuticals and targeted molecular imaging agents for use in oncology and cardiology. Molecular Insight has five clinical-stage candidates in development.

Nile Therapeutics, Inc

admin — Sun, 21 Feb 2010 13:59:34 +0000

Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical needs. Nile is initially focusing its efforts on developing its lead compound, CD-NP, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure, and CU-NP, a novel rationally designed natriuretic peptide.

Imarx Therapeutics, Inc.

admin — Sat, 20 Feb 2010 18:16:31 +0000

ImaRx Therapeutics is a development-stage biopharmaceutical company with a research and development program focused on the development of new treatments for vascular disorders leveraging its proprietary microsphere and ultrasound or SonoLysis technology.

Cardiovascular Systems Inc.

admin — Sun, 14 Feb 2010 12:50:41 +0000

Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing interventional treatment systems for vascular disease. The company’s Diamondback 360(R) PAD System treats calcified and fibrotic plaque in arterial vessels throughout the leg in a few minutes of treatment time, and addresses many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives. As many as 12 million Americans suffer from peripheral arterial disease (PAD), which is caused by the accumulation of plaque in peripheral arteries (commonly the pelvis or leg) reducing blood flow. Symptoms include leg pain when walking or at rest, and can lead to tissue loss and eventually limb amputation. In August 2007, the U.S. FDA granted 510(k) clearance for the use of the Diamondback 360

Bioheart, Inc.

admin — Fri, 12 Feb 2010 23:36:36 +0000

Bioheart is a biotechnology company focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic, acute heart damage, and peripheral vascular disease.

ARCA biopharma, Inc.

admin — Fri, 12 Feb 2010 22:25:54 +0000

ARCA biopharma, Inc. is a biopharmaceutical company developing genetically-targeted therapies for heart failure and other cardiovascular diseases. ARCA biopharma began operations in 2005 and is headquartered in Broomfield, Colorado.

The Company’s lead investigational product is Gencaro™ (bucindolol hydrochloride), a genetically-targeted beta-blocker with unique pharmacology, in development for heart failure and other indications.